Bines, et al. Human. New Eng­land Jour­nal of Med­i­cine. 2018


In healthy term neonates, is oral human rotavirus vac­cine admin­is­tered on a neona­tal sched­ule or infant sched­ule more effec­tive than place­bo at pre­vent­ing rotavirus gas­troen­teri­tis until age 18 months?
Design: A ran­domised, dou­ble-blind, par­al­lel group, place­bo-con­trolled tri­al. Oral human rotavirus vac­cine (RV3-BB) was admin­is­tered on a neona­tal sched­ule (0–5 days, 8 weeks, and 14 weeks of age), or an infant sched­ule (8 weeks, 14 weeks, and 18 weeks of age), or as a place­bo.


The admin­is­tra­tion of a human neona­tal rotavirus vac­cine (RV3-BB), via a neona­tal or infant vac­cine sched­ule, is effi­ca­cious in pre­vent­ing severe gas­troen­teri­tis until 18 months of age in chil­dren in Indone­sia.

  • Next Conference Port-Said Neonatology 15/10/2019